Immune response, inflammation, and the clinical spectrum of COVID-19

LF García - Frontiers in immunology, 2020 - frontiersin.org
The current COVID-19 pandemic began in December 2019 in Wuhan (China) and rapidly
extended to become a global sanitary and economic emergency. Its etiological agent is the …

[HTML][HTML] Immunology of COVID-19: current state of the science

N Vabret, GJ Britton, C Gruber, S Hegde, J Kim… - Immunity, 2020 - cell.com
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting …

The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions In Vivo

S Biradar, Y Agarwal, MT Lotze, MT Bility… - Frontiers in …, 2022 - frontiersin.org
Gamma-delta (γδ) T cells recognize antigens in a major histocompatibility complex (MHC)
independent and have cytotoxic capability. Human immunodeficiency virus (HIV) infection …

Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?

G Zizzo, PL Cohen - The Lancet Rheumatology, 2020 - thelancet.com
The unique cytokine signature of COVID-19 might provide clues to disease mechanisms and
possible future therapies. Here, we propose a pathogenic model in which the alarmin …

Immune responses in mildly versus critically ill COVID-19 patients

H Nasrollahi, AG Talepoor, Z Saleh… - Frontiers in …, 2023 - frontiersin.org
The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had
devastating effects on the global health and economic system. The cellular and molecular …

Adaptive immune cells are necessary for SARS-CoV-2–induced pathology

B Imbiakha, JM Sahler, DW Buchholz, S Ezzatpour… - Science …, 2024 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing
global pandemic associated with morbidity and mortality in humans. Although disease …

Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity

AT Ambikan, H Yang, S Krishnan, SS Akusjärvi… - Cell systems, 2022 - cell.com
The clinical outcome and disease severity in coronavirus disease 2019 (COVID-19) are
heterogeneous, and the progression or fatality of the disease cannot be explained by a …

COVID-19: immunology, immunopathogenesis and potential therapies

A Bhardwaj, L Sapra, C Saini, Z Azam… - International reviews …, 2022 - Taylor & Francis
Abstract The Coronavirus Disease-2019 (COVID-19) imposed public health emergency and
affected millions of people around the globe. As of January 2021, 100 million confirmed …

A machine-generated view of the role of blood glucose levels in the severity of COVID-19

E Logette, C Lorin, C Favreau, E Oshurko… - Frontiers in Public …, 2021 - frontiersin.org
SARS-CoV-2 started spreading toward the end of 2019 causing COVID-19, a disease that
reached pandemic proportions among the human population within months. The reasons for …

Cellular and humoral immune responses in covid-19 and immunotherapeutic approaches

A Hasan, E Al-Ozairi, Z Al-Baqsumi… - ImmunoTargets and …, 2021 - Taylor & Francis
Abstract Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from …